Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
ADC ID |
DRG0ZGUAA
|
|||||
---|---|---|---|---|---|---|
ADC Name |
B4-SMCC-DC4
|
|||||
Synonyms |
B4-SMCC DC4
Click to Show/Hide
|
|||||
Drug Status |
Investigative
|
|||||
Indication |
In total 2 Indication(s)
Acute promyelocytic leukemia [ICD11:2A60]
Investigative
Burkitt lymphoma [ICD11:2A85]
Investigative
|
|||||
Drug-to-Antibody Ratio |
3.5-5
|
|||||
Structure | ||||||
Antibody Name |
Anti-CD19 mAb B4
|
Antibody Info | ||||
Antigen Name |
B-lymphocyte antigen CD19 (CD19)
|
Antigen Info | ||||
Payload Name |
Phosphate prodrugs 40 (DC4)
|
Payload Info | ||||
Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
Linker Name |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
|
Linker Info | ||||
Conjugate Type |
Lysine residue on the antibody is conjugated via an amide bond to the linker-payload moiety.
|
|||||
Combination Type |
SMCC-DC4
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.20 nM | Positive CD19 expression (CD19+++/++) | ||
Method Description |
Cytotoxicity of B4-SPP-DCx Conjugates (with acid phosphatase treatment) against Ramos (Ag+) and HL60/s (Ag-) Cells.
|
||||
In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.60 nM | Negative CD19 expression(CD19-) | ||
Method Description |
Cytotoxicity of B4-SPP-DCx Conjugates (with acid phosphatase treatment) against Ramos (Ag+) and HL60/s (Ag-) Cells.
|
||||
In Vitro Model | Adult acute myeloid leukemia | HL-60 cells | CVCL_0002 |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.